Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Antiviral drug screen identifies DNA-damage response inhibitor as potent blocker of SARS-CoV-2 replication

Cell Reports(2021)10.1016/j.celrep.2021.108940Source: DataRank Database

Antiviral drug screen identifies DNA-damage response inhibitor as potent blocker of SARS-CoV-2 replication is a research paper published in Cell Reports (2021). On theSindex it has a DataRank of 0. It has been cited 119 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access119 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (21 grants)Impact (FWCI 6.07)OA: goldTopics (126)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (28)

Arun Sharma ORCID,Arunachalam Ramaiah ORCID,Chandani Sen ORCID,Arunima Purkayastha,Donald B. Kohn ORCID

Live enrichment

PubMed:33784499 PMC:PMC7969873 OpenAlex:https://openalex.org/W3136337343

David Geffen School of Medicine, University of California, Los Angeles

Grant: OCRC 20-15

National Eye Institute

Grant: 1R01EY032149

Bill and Melinda Gates Foundation

Grant: INV-018812

Bill and Melinda Gates Foundation

Grant: OPP1208899

American Heart Association Inc

Grant: AHA 814630

Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California Los Angeles

Grant: OCRC 20-14

California Institute for Regenerative Medicine

Grant: TRAN1COVID19-11975

California Institute for Regenerative Medicine

Grant: DISC2COVID19-11764

California Institute for Regenerative Medicine

Grant: T32 HL116273

NINR NIH HHS

Grant: R21 NR010361

NCI NIH HHS

Grant: P30 CA016042

NIDDK NIH HHS

Grant: R01 DK132735

NEI NIH HHS

Grant: R01 EY032149

National Institutes of Health

Grant: 3P30CA016042-35S3

Cancer Center Support Grant

National Institutes of Health

Grant: 5T32HL116273-09

Training in Advanced Heart Disease Research

National Institutes of Health

Grant: 5R01EY032149-03

Interplay between AMPK and Hippo Signaling Regulates Ocular Antiviral Response to Zika virus infection

CIRM

American Heart Association Inc

National Eye Institute

Bill and Melinda Gates Foundation

National Cancer Institute

FWCI

6.07

Citation Percentile

1.0%

Citation Trend

2021

2022

2023

2024

2025

2026

goldLicense: cc-by

journalhttp://www.cell.com/article/S2211124721002540/pdf

publisherhttp://www.cell.com/article/S2211124721002540/pdf

publisherhttps://api.elsevier.com/content/article/PII:S2211124721002540?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2211124721002540?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.celrep.2021.108940

Fields of Study

SARS-CoV-2 and COVID-19 ResearchPARP inhibition in cancer therapyCell death mechanisms and regulation0301 basic medicine0303 health sciences03 medical and health sciences

MeSH Terms

A549 CellsCOVID-19SARS-CoV-2COVID-19 Drug TreatmentAnimalsAntiviral AgentsChlorocebus aethiopsDNA DamageDrug Evaluation, PreclinicalHeLa CellsHumansIsoxazolesPyrazinesVero CellsVirus ReplicationMAP Kinase Signaling SystemHEK293 CellsMiddle East Respiratory Syndrome CoronavirusHela Cells

Keywords

Viral replicationDrug discoveryBiologyPI3K/AKT/mTOR pathwayCoronavirusCytopathic effectAntiviral drugKinaseProtein kinase BMiddle East respiratory syndrome coronavirusVirologyDrugViral entrySignal transductionCell biologyVirusPharmacologyMedicineBioinformaticsCoronavirus disease 2019 (COVID-19)Protein Kinase InhibitorsNucleoside AnalogsHigh-throughput ScreenAtr KinaseCovid-19Sars-cov-2Dna-Damage Response PathwayMtor-Pi3k-Akt PathwayBerzosertibMiddle East Respiratory Syndrome Coronavirus (mesh)Coronaviruses3102 Bioinformatics and Computational Biology (for-2020)Medical PhysiologyDrug Evaluation, PreclinicalVirus ReplicationLung (rcdc)Coronaviruses Therapeutics and Interventions31 Biological sciences (for-2020)Chlorocebus aethiopsAnimals (mesh)Hela Cells (mesh)Biology (General)LungCancerCancer (rcdc)Humans (mesh)3 Good Health and Well Being (sdg)COVID-19 (mesh)COVID-19 Drug Treatment (mesh)Biological SciencesPreclinical1116 Medical Physiology (for)Infection (hrcs-hc)Infectious Diseases5.1 PharmaceuticalsPyrazinesInfectionQH301-705.5MAP Kinase Signaling SystemAntiviral Agents (mesh)Virus Replication (mesh)Bioinformatics and Computational BiologyIsoxazoles (mesh)0601 Biochemistry and Cell Biology (for)610Coronaviruses Therapeutics and Interventions (rcdc)SARS-CoV-2 (mesh)A549 Cells (mesh)DNA Damage (mesh)Antiviral AgentsEmerging Infectious Diseases (rcdc)MAP Kinase Signaling System (mesh)Rare Diseases (rcdc)Rare Diseases5.1 Pharmaceuticals (hrcs-rac)BiodefenseReport616AnimalsHumansBiodefense (rcdc)Preclinical (mesh)Vero CellsHEK293 Cells (mesh)Pyrazines (mesh)Coronaviruses (rcdc)IsoxazolesVero Cells (mesh)COVID-19 Drug TreatmentOrphan DrugEmerging Infectious DiseasesGood Health and Well BeingHEK293 CellsInfectious Diseases (rcdc)A549 CellsChlorocebus aethiops (mesh)Orphan Drug (rcdc)Drug EvaluationBiochemistry and Cell BiologyDNA DamageHeLa Cells

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Antiviral drug screen identifies DNA-damage response inhibitor as potent blocker of SARS-CoV-2 replication

FAIR Checklist

Authors (28)

Funding (21 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)